CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 7.61: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
270.68MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.5300xvs all stocks
52-Week Change
31.11%vs all stocks
Market Capitalization
270.68MUSDvs all stocks (USD)
Enterprise Value
179.02MUSDvs all stocks (USD)
Forward P/E
-3.74xvs Biotechnology peers
Price to Book (MRQ)
1.22xvs Biotechnology peers
Enterprise to EBITDA
-3.25xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.37%vs Biotechnology peers
Return on Equity (TTM)
-0.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
-39.09MUSDvs all stocks (USD)
EBITDA (TTM)
-55.12MUSDvs all stocks (USD)
Net Income (TTM)
-9.41MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-51.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-48.95MUSDvs all stocks (USD)
Pre-tax Income
13.27MUSDFY2025 · Dec 31, 2025Net Income
13.27MUSDFY2025 · Dec 31, 2025EBIT
13.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-46.16MUSDFY2025 · Dec 31, 2025Research & Development
34.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
14.60MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
240.66KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
13.27MUSDFY2025 · Dec 31, 2025Operating Cash Flow
22.40MUSDFY2025 · Dec 31, 2025Free Cash Flow
21.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
10.50MUSDFY2025 · Dec 31, 2025Interest Paid
242.03KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
13.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.08MUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.21MUSDFY2025 · Dec 31, 2025Other Non-cash Items
172.47KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-891.83KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.48MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
67.42KUSDFY2025 · Dec 31, 2025Capital Expenditures
-932.66KUSDFY2025 · Dec 31, 2025Purchase of Investments
-142.04MUSDFY2025 · Dec 31, 2025Sale of Investments
21.26MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-121.71MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-418.41KUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-275.85KUSDFY2025 · Dec 31, 2025Other Financing Charges
-11.96KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
168.02MUSDFY2025 · Dec 31, 2025Shares Outstanding
75.74MSharesUpdated Jul 19, 2026Float Shares
41.20MSharesUpdated Jul 19, 2026Shares Short
3.77MSharesUpdated Jul 19, 2026Short Ratio
3.34daysvs all stocks
Short % of Shares Outstanding
5.12%vs all stocks
% Held by Insiders
0.84%vs all stocks
% Held by Institutions
91.93%vs all stocks
Total Cash (MRQ)
107.39MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.40USDUpdated Jul 19, 2026Total Debt (MRQ)
6.17MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0272xvs Biotechnology peers
Current Ratio (MRQ)
11.45xvs Biotechnology peers
Book Value per Share (MRQ)
3.00USDUpdated Jul 19, 2026Total Assets
172.81MUSDvs all stocks (USD)
Total Current Assets
101.05MUSDFY2025 · Dec 31, 2025Total Liabilities
21.32MUSDFY2025 · Dec 31, 2025Total Non-current Assets
71.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
10.63MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
10.50MUSDFY2025 · Dec 31, 2025Other Short-term Investments
86.09MUSDFY2025 · Dec 31, 2025Accounts Payable
3.15MUSDFY2025 · Dec 31, 2025Short-term Debt
951.37KUSDFY2025 · Dec 31, 2025Long-term Debt
5.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.77KUSDFY2025 · Dec 31, 2025Retained Earnings
-110.90MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
151.49MUSDvs all stocks (USD)
Treasury Stock
5.52MUSDFY2025 · Dec 31, 202552-Week Low
1.85USDUpdated Jul 19, 202652-Week High
6.60USDUpdated Jul 19, 202652-Week Change
31.11%vs all stocks
Beta
0.5300xvs all stocks
50-Day MA
3.72USDUpdated Jul 19, 2026200-Day MA
3.65USDUpdated Jul 19, 2026Avg 10-Day Volume
495.74KSharesUpdated Jul 19, 2026Avg 30-Day Volume
933.47KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.5800USDUpdated Jul 19, 2026Other Income / Expense
61.04MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.61: safe zoneNotable
Altman Z-Score: 7.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Aurinia Pharmaceuticals Inc.
2 interpretationsFCF Ratios ElevatedMinimal Tax and Interest Drag
Strait Innovation Internet Co., Ltd.
2 interpretationsFCF Ratios ElevatedMinimal Tax and Interest Drag
SM Entertainment Co., Ltd.
2 interpretationsFCF Ratios ElevatedMinimal Tax and Interest Drag